Morepen Labs Q1 FY27: Revenue ₹575 Cr, EBITDA ₹87 Cr, PAT ₹56 Cr
Morepen Laboratories reported a record Q1 FY27 revenue of ₹575.31 crore, up 34% YoY. EBITDA surged 207% to ₹87.72 crore, with margins at 15.25%. PAT increased 394% to ₹56.35 crore. Export revenue grew 111%. The company is expanding manufacturing capacity to 1200 KL and sees its CDMO business as a key growth driver.
The announcement details record financial performance, substantial growth across key metrics, and strategic expansion plans, which are material events likely to impact investor perception and the company's stock value.
The company reported record quarterly revenue, significant year-on-year growth in revenue, EBITDA, and PAT, along with strong export performance and capacity expansion plans, indicating a positive financial and operational outlook.
Morepen Laboratories Limited announced its financial results for the first quarter of FY27, ending June 30, 2026. The company reported its highest ever quarterly revenue of ₹575.31 crore, a significant increase of 34% year-on-year. The Contract Development and Manufacturing Organization (CDMO) mandate has entered the commercial supply phase, contributing to this growth. The company also achieved its highest ever quarterly EBITDA of ₹87.72 crore, a substantial increase of 207% year-on-year, with EBITDA margins improving to 15.25% from 6.65% in the prior year. Profit After Tax (PAT) surged by 394% to ₹56.35 crore.
Export revenue saw a remarkable increase of 111% year-on-year. The API business demonstrated a 31% growth, with API exports up by 42%. The company highlighted a strategic transition from commodity APIs to innovation-led manufacturing, emphasizing its growing CDMO business which is characterized by long-duration customer programs, recurring revenues, and higher margins.
Morepen Laboratories is also expanding its manufacturing capacity, with plans to scale up from 600 KL to 1200 KL by Q4 FY27, with further phases extending to FY30. The medical devices segment is being developed as a second scalable growth engine, focusing on chronic care with recurring consumables revenue.
The company's regulatory track record remains strong, with no 483 observations in four consecutive USFDA inspections and compliance with GMP standards. The outlook for the near term includes continued commercial CDMO supplies, API profitability recovery, and increased capacity utilization. For the medium term, the focus is on capacity augmentation and new customer opportunities, while the long term vision is centered on innovation-led manufacturing and sustainable value creation.
What to do with a filing like this
Morepen Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Morepen Laboratories Limited. Read the original for the full detail.